Company / Free Cash Flow
Compass Therapeutics, Inc. Free Cash Flow History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$44.9M
FY2024
5-year range
-$44.9M / -$21.2M
FY2020-FY2024
Trend
-10.5%
vs FY2023
Sector context
#79 of 195
Health Care
What the data says
At -$45M, Compass Therapeutics, Inc.'s free cash flow ranks #79 of 195 in the Health Care sector. Free Cash Flow has declined for 3 consecutive years, from -$21M in FY2021 to -$45M in FY2024.
Based on SEC 10-K filings.
-$45M in FY2024.
Declined from -$34M to -$45M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#79 of 195 in Health CareTop 41% of 195This company -$44.9M Sector average $467.5M
▼
-109.6% below sector average
Key checks
Key Insights
- Compass Therapeutics, Inc.'s free cash flow has declined for 3 consecutive years.
- In FY2024, free cash flow decreased 10.5% year-over-year.
- Ranks #79 out of 195 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$44.9M | -10.5% |
| FY2023 | -$40.6M | -18.4% |
| FY2022 | -$34.3M | -61.7% |
| FY2021 | -$21.2M | +21.1% |
| FY2020 | -$26.9M | +16.4% |
| FY2019 | -$32.2M | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026